{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T16:53:29Z","timestamp":1773507209179,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","redjournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ijrobp.2024.11.010","type":"journal-article","created":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T02:01:09Z","timestamp":1731722469000},"page":"875-884","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ten-Year Outcomes of a Phase 3, Multicenter, Randomized Controlled Trial (SHIP0804) With 3-Month Neoadjuvant Androgen Deprivation Prior to 125I-Seed Transperineal Prostate Brachytherapy Followed by Nil Versus 9-Month Adjuvant Hormonal Therapy in Patients With Intermediate-Risk Prostate Cancer"],"prefix":"10.1016","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1044-912X","authenticated-orcid":false,"given":"Wataru","family":"Fukuokaya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenta","family":"Miki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiro","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsunori","family":"Yorozu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takushi","family":"Dokiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Egawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2024.11.010_bib0001","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2024.11.010_bib0002","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300018","article-title":"Patient-reported outcomes 12 years after localized prostate cancer treatment","volume":"2","author":"Donovan","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.ijrobp.2024.11.010_bib0003","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.ijrobp.2010.01.006","article-title":"Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?","volume":"79","author":"Kuban","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.11.010_bib0004","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.ijrobp.2010.03.049","article-title":"70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial","volume":"80","author":"Beckendorf","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.11.010_bib0005","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(10)70223-0","article-title":"External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study","volume":"11","author":"Bolla","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2024.11.010_bib0006","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1002\/cncr.29420","article-title":"Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease","volume":"121","author":"Keane","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2024.11.010_bib0007","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1200\/JCO.22.02390","article-title":"Dose-escalated radiotherapy alone or in combination with short-term androgen deprivation for intermediate-risk prostate cancer: results of a phase III multi-institutional trial","volume":"41","author":"Krauss","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.11.010_bib0008","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1200\/JCO.21.00855","article-title":"Short androgen suppression and radiation dose escalation in prostate cancer: 12-year results of EORTC trial 22991 in patients with localized intermediate-risk disease","volume":"39","author":"Bolla","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.11.010_bib0009","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.brachy.2011.07.005","article-title":"American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy","volume":"11","author":"Davis","year":"2012","journal-title":"Brachytherapy"},{"key":"10.1016\/j.ijrobp.2024.11.010_bib0010","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrurol.2017.76","article-title":"The evolution of brachytherapy for prostate cancer","volume":"14","author":"Zaorsky","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.ijrobp.2024.11.010_bib0011","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.11.010_bib0012","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa032975","article-title":"Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy","volume":"351","author":"D'Amico","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2024.11.010_bib0013","series-title":"TNM Atlas","author":"Wittekind","year":"2014"},{"key":"10.1016\/j.ijrobp.2024.11.010_bib0014","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/pin.12260","article-title":"Results of central pathology review of prostatic biopsies in a contemporary series from a phase III, multicenter, randomized controlled trial (SHIP0804)","volume":"65","author":"Sasaki","year":"2015","journal-title":"Pathol Int"},{"key":"10.1016\/j.ijrobp.2024.11.010_bib0015","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1097\/01.pas.0000173646.99337.b1","article-title":"The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma","volume":"29","author":"Epstein","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ijrobp.2024.11.010_bib0016","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","article-title":"The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system","volume":"40","author":"Epstein","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ijrobp.2024.11.010_bib0017","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1186\/1471-2407-10-572","article-title":"Transperineal prostate brachytherapy, using I-125 seed with or without adjuvant androgen deprivation, in patients with intermediate-risk prostate cancer: study protocol for a phase III, multicenter, randomized, controlled trial","volume":"10","author":"Miki","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijrobp.2024.11.010_bib0018","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1118\/1.597458","article-title":"Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. American Association of Physicists in Medicine","volume":"22","author":"Nath","year":"1995","journal-title":"Med Phys"},{"key":"10.1016\/j.ijrobp.2024.11.010_bib0019","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.ijrobp.2004.08.003","article-title":"Prostate seed implantation using 3D-computer assisted intraoperative planning vs. a standard look-up nomogram: Improved target conformality with reduction in urethral and rectal wall dose","volume":"60","author":"Raben","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.11.010_bib0020","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2024.11.010_bib0021","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0360-3016(01)01539-5","article-title":"Five-year biochemical outcome after prostate brachytherapy for hormone-naive men < or = 62 years of age","volume":"50","author":"Merrick","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.11.010_bib0022","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/cncr.20093","article-title":"Recurrence-free survival rates after external-beam radiotherapy for patients with clinical T1-T3 prostate carcinoma in the prostate-specific antigen era: what should we expect?","volume":"100","author":"Khuntia","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2024.11.010_bib0023","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0360-3016(98)00006-6","article-title":"A dose-response study for I-125 prostate implants","volume":"41","author":"Stock","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.11.010_bib0024","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ijrobp.2009.04.052","article-title":"Biologically effective dose (BED) correlation with biochemical control after low-dose rate prostate brachytherapy for clinically low-risk prostate cancer","volume":"77","author":"Miles","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.11.010_bib0025","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ijrobp.2009.02.021","article-title":"Natural history of clinically staged low- and intermediate-risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy","volume":"76","author":"Taira","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.11.010_bib0026","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1097\/01.ju.0000154633.73092.8e","article-title":"12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer","volume":"173","author":"Potters","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2024.11.010_bib0027","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1111\/j.1464-410X.2008.08255.x","article-title":"Concordance between Gleason scores of needle biopsies and radical prostatectomy specimens: a population-based study","volume":"103","author":"Kv\u00e5le","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.ijrobp.2024.11.010_bib0028","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/s41391-021-00323-6","article-title":"Long-term biopsy outcomes in prostate cancer patients treated with external beam radiotherapy: a systematic review and meta-analysis","volume":"24","author":"Singh","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ijrobp.2024.11.010_bib0029","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.brachy.2022.01.001","article-title":"Factors associated with late local failure and its influence on survival in men undergoing prostate brachytherapy","volume":"21","author":"Stone","year":"2022","journal-title":"Brachytherapy"},{"key":"10.1016\/j.ijrobp.2024.11.010_bib0030","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ijrobp.2023.08.046","article-title":"Trimodality therapy with iodine-125 brachytherapy, external beam radiation therapy, and short- or long-term androgen deprivation therapy for high-risk localized prostate cancer: results of a multicenter, randomized phase 3 trial (TRIP\/TRIGU0907)","volume":"118","author":"Yorozu","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.11.010_bib0031","doi-asserted-by":"crossref","first-page":"E44","DOI":"10.1111\/bju.12166","article-title":"The relative importance of hormonal therapy and biological effective dose in optimizing prostate brachytherapy treatment outcomes","volume":"112","author":"Stock","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.ijrobp.2024.11.010_bib0032","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1200\/JOP.18.00178","article-title":"Cardiovascular and metabolic effects of androgen-deprivation therapy for prostate cancer","volume":"14","author":"Gupta","year":"2018","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.ijrobp.2024.11.010_bib0033","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ijrobp.2017.08.042","article-title":"Brachytherapy for intermediate-risk prostate cancer, androgen deprivation, and the risk of death","volume":"100","author":"Pickles","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.11.010_bib0034","doi-asserted-by":"crossref","first-page":"378","DOI":"10.21037\/tau.2018.01.06","article-title":"Adjuvant androgen deprivation therapy for prostate cancer treated with radiation therapy","volume":"7","author":"Siddiqui","year":"2018","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.ijrobp.2024.11.010_bib0035","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1200\/JCO.19.03114","article-title":"Event-free survival, a prostate-specific antigen-based composite end point, is not a surrogate for overall survival in men with localized prostate cancer treated with radiation","volume":"38","author":"Xie","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301624035843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301624035843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:47:36Z","timestamp":1740134856000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301624035843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0360301624035843"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2024.11.010","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ten-Year Outcomes of a Phase 3, Multicenter, Randomized Controlled Trial (SHIP0804) With 3-Month Neoadjuvant Androgen Deprivation Prior to 125I-Seed Transperineal Prostate Brachytherapy Followed by Nil Versus 9-Month Adjuvant Hormonal Therapy in Patients With Intermediate-Risk Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2024.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}